Liu Yanming, Zhang Feiyue, Zhang Zhaobo, Wang Daoqing, Cui Baojuan, Zeng Fanshuo, Huang Laigang, Zhang Qi, Sun Qiangsan
Department of Rehabilitation, The Second Hospital of Shandong University, Shandong University, Jinan, Shandong 250033, PR China; Department of Physical Medicine and Rehabilitation, Zibo Central Hospital, Zibo, Shandong 255036, PR China.
Department of Obstetrics, Zibo Central Hospital, Zibo, Shandong 255036, PR China.
Pathol Res Pract. 2017 Aug;213(8):895-899. doi: 10.1016/j.prp.2017.06.004. Epub 2017 Jun 6.
Cysteine Rich Angiogenic Inducer 61 (Cyr61) and Vascular Endothelial Growth Factor (VEGF) are signaling proteins involved in the regulation of tumor angiogenesis and progression. The purpose of this study was to investigate the clinicopathological and prognostic significance of Cyr61 and VEGF expressions in osteosarcoma. Immunohistochemical staining was performed to evaluate the expression of both the proteins in 84 osteosarcoma samples. Correlation between Cyr61/VEGF expressions and clinicopathological parameters was determined using Rank sum test and Spearman's rank correlation coefficient. Prognostic factors were identified using univariate and multivariate Cox regression analysis. The expressions of Cyr61 and VEGF were weak in 26.2% and 17.9%, moderate in 26.2% and 23.8%, and strong in 47.6% and 58.3% of osteosarcoma samples, respectively. Cyr61 and VEGF expressions moderately correlated with each other in osteosarcoma, and exhibited significant association with Enneking stage and distant metastasis. In addition, the high expression of both proteins significantly correlated with short overall survival time in these patients. The key finding in this study was that both Cyr61 and VEGF expressions were independent prognostic indicators of overall survival. In summary, our results indicate that expression of Cyr61 and VEGF may serve as important prognostic predictors in patients with osteosarcoma.
富含半胱氨酸的血管生成诱导因子61(Cyr61)和血管内皮生长因子(VEGF)是参与肿瘤血管生成和进展调控的信号蛋白。本研究旨在探讨Cyr61和VEGF表达在骨肉瘤中的临床病理及预后意义。采用免疫组织化学染色法评估84例骨肉瘤样本中这两种蛋白的表达。使用秩和检验和Spearman秩相关系数确定Cyr61/VEGF表达与临床病理参数之间的相关性。采用单因素和多因素Cox回归分析确定预后因素。在骨肉瘤样本中,Cyr61和VEGF的表达分别有26.2%和17.9%为弱阳性,26.2%和23.8%为中等阳性,47.6%和58.3%为强阳性。在骨肉瘤中,Cyr61和VEGF表达呈中度相关,并与Enneking分期和远处转移显著相关。此外,这两种蛋白的高表达与这些患者较短的总生存时间显著相关。本研究的关键发现是Cyr61和VEGF表达均为总生存的独立预后指标。总之,我们的结果表明,Cyr61和VEGF的表达可能是骨肉瘤患者重要的预后预测指标。